Contrasting Ginkgo Bioworks (NYSE:DNA) and Bullfrog AI (NASDAQ:BFRGW)

Bullfrog AI (NASDAQ:BFRGW) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Bullfrog AI and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bullfrog AI and Ginkgo Bioworks, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0	0	0	0	0.00
Ginkgo Bioworks	2	2	0	0	1.50

Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential upside of 2.79%. Given Ginkgo Bioworks’ stronger consensus rating and higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Bullfrog AI.

Earnings & Valuation

This table compares Bullfrog AI and Ginkgo Bioworks”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298,798.00	N/A	N/A	N/A	N/A
Ginkgo Bioworks	$170.15 million	2.70	-$312.76 million	($5.01)	-1.36

Bullfrog AI has higher earnings, but lower revenue than Ginkgo Bioworks.

Summary

Ginkgo Bioworks beats Bullfrog AI on 5 of the 8 factors compared between the two stocks.

About Bullfrog AI

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.